The Tirzepatide segment is expected to grow at the fastest CAGR in the coming years, driven by a dual GIP and GLP-1 receptor mechanism providing better results for weight loss
This transparency allows California patients to dose up to therapeutic levels without worrying about sudden cost jumps that often force people to stay at suboptimal, less effective doses
Yes, common side effects include nausea, abdominal pain or discomfort, and diarrhea, though they subside over time
They are signs the drug is working on your gut motility and your central nervous system appetite pathways simultaneously
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a type of medication originally developed to treat type 2 diabetes, but are now being used for the treatment of obesity because they are effective at helping people to lose weight
This effect is thought to result from increased free fatty acid release from adipose tissue and hepatic glucose production